Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Amgen says it expects pandemic to limit sales through 2021

Stock Markets Aug 03, 2021 06:01PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith

By Deena Beasley

(Reuters) - U.S. biotech Amgen Inc (NASDAQ:AMGN) on Tuesday said its second-quarter revenue rose 5%, but recovery from the COVID-19 pandemic, which has limited patient interactions with healthcare providers, is expected to hit sales for the rest of 2021.

The pandemic "has suppressed the volume of new patients starting treatment," the company said in a statement.

Amgen also said more competition, including from cheaper generics and biosimilars, would continue to pressure its net selling prices, especially for its cholesterol, psoriasis and infection-fighting drugs.

In addition, the company said it is contesting in the U.S. Tax Court notices from the Internal Revenue Service seeking to increase its taxable income in three prior years by an amount that would result in additional federal tax of around $3.6 billion, plus interest.

The dispute, which will take several years to resolve, involves Amgen's accounting for profits between the United States and Puerto Rico, the location of most of its manufacturing operations, Chief Financial Officer Peter Griffith said on a conference call with investors.

Amgen's quarterly adjusted earnings, helped by share buybacks, rose 4% from a year earlier to $4.38 per share, beating the $4.10 forecast by Wall Street analysts, as calculated by Refinitiv.

The results "look generally straightforward," but the commentary on the pandemic "will moderate enthusiasm," Jefferies (NYSE:JEF) analyst Michael Yee said in an emailed comment.

Amgen shares, which rose 1.8% to close at $244.08, were trading lower at $242 after hours.

Revenue of $6.5 billion was in line with analyst estimates as an 8% increase in unit sales volumes was partially offset by a 5% drop in net selling prices.

For the full year, Amgen said it still expects adjusted earnings of $16.00 to $17.00 per share on revenue of $25.8 billion to $26.6 billion.

But the company lowered its 2021 net earnings estimate to $8.84 to $9.90 per share from its prior view of $9.11 to $10.71, and said share repurchases will be at the upper end of its previous estimate of $3 billion to $5 billion.

"This will raise eyebrows a bit given they typically raise guidance for the second half of the year," Yee said.

Sales of newer migraine drug Aimovig fell 16% from a year earlier to $82 million, short of the $95 million projected by analysts. Sales of cholesterol fighter Repatha rose 43% to $286 million, but it too missed Wall Street estimates of $299 million.

Amgen also announced on Tuesday plans to build a new drug substance manufacturing facility in Holly Springs, North Carolina.

Amgen says it expects pandemic to limit sales through 2021
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email